English Extended Distribution PR-Wirein Press Release Reportedtimes Research Newswire

Global D-Phenylalanine Market Size Estimated To Reach $1,538.7 Million by 2027

The Global D-Phenylalanine Market size is estimated to reach $1,538.7 million by 2027. Furthermore, it is poised to grow at a CAGR of 5.4% over the forecast period of 2022-2027. D-Phenylalanine has been effectively used as an anti-depressant and for treating chronic illnesses. Ammonium hydroxide has been effectively used as a key step for the synthesis of tyrocidine, a chemical messenger induced which plays a part in reducing depressive symptoms. Teichoic acids and lipoteichoic acids are the components of cell walls, and cytoplasmic membranes, respectively, in Gram-positive bacteria; they contain a linear poly(glycerophosphate) chain and carry D-alanine ester in variable amounts. Additionally, mass spectrometry- electrochemical-have been employed in determining neuroactive molecules. Furthermore, the Pictet-Spengler reaction has been used to synthesize the overall tricyclic vabicaserin. Growing cases of depression, lower back pain, and various other forms of diseases have been a key factor driving the Global D-Phenylalanine Industry forward in the projected period of 2022-2027.

Global D-Phenylalanine Market Segment Analysis- By Type

The global D-phenylalanine market based on type can be further segmented into food grade, pharmaceutical grade, and feed grade. Pharmaceutical grade held a dominant market share in the year 2021. It is owing to the widespread use of phenylalanine in various medicinal properties. Additionally, the global burden of diseases is growing, and private players have been the first to respond in conducting clinical studies. As per INCYTE, a pharmaceutical company, spent close to $2.216 billion in 2020, which was nearly $1 billion more than 2019. Similar trends were noticed in major pharma companies. Moreover, pharmaceutical grade is estimated to be the fastest-growing, with a CAGR of 5.7% over the forecast period of 2022-2027. It is owing to the rising concerns of various global companies to combat the growing antibacterial resistance diseases, coupled with treating mental health ailments.

Request for Sample Report @ https://www.industryarc.com/pdfdownload.php?id=513387

Report Price: $ 5900 (Single User License)

Global D-Phenylalanine Market Segment Analysis- By Application

The Global D-Phenylalanine Market based on the application can be further segmented into Depression, Lower Back Pain, Parkinson’s Disease, Osteoarthritis, and Others. Depression held a dominant market share in the year 2021. D-DL phenylalanine has been typically recommended by physicians to treat depression, the dose for which has been recommended at 100-200 mg daily. The global burden of depression has been rising, specifically, in high-and middle-income countries where the job attrition rates are high or other hyper-inducing stress factors are more. As per WHO, around 5% of the entire population suffers from depressive disorders. However, chronic pain is estimated to be the fastest-growing, with a CAGR of 6.3% over the forecast period of 2022-2027. Chronic pain can be effectively treated, as the said amino acid blocks enkephalinase, an enzyme that is responsible for increased pain levels in the body. Growing geriatric population coupled with a high disease burden, especially in chronic pain management would act as a key driver.

Global D-Phenylalanine Market Segment Analysis- By Geography

The global d-phenylalanine market based on Geography can be further segmented into North America, Europe, Asia-Pacific, South America, and Rest of the World. North America held a dominant market share of 36% in the year 2021. It is owing to the presence of both factors, for one, robust demand is catered by the regions such as the U.S. and Canada for various applicative uses such as helping depression or relieving various forms of pain. Secondly, the presence of robust medical infrastructure allows for optimal use of such ingredients. The U.S. spends around $11,530 per person each year in form of medical expenditure, which is by far the highest in the World. Additionally, the North American region would offer lucrative growth opportunities to marketers in the projected period of 2022-2027. It is owing to the medical budget of the country growing faster than the GDP, showing a resilient featurette of the market.

Global D-Phenylalanine Market Drivers

A growing concern for people suffering from various forms of pain supplemented by the geriatric age has been a key driver.

The geriatric population has been blooming, and so, the medical infrastructure has been a key driver. However, the growing population leads to other forms of problems. Moreover, as per WHO estimates, 524 million people were above the threshold of 65+, which is expected to touch 1.5 billion in 2050. Lower back pain has been a prevalent condition. As per the International Association for the Study of Pain, around 7.5% of the global population of around 577 million people globally suffer from lower back pain. 85-95% of people presenting to primary care providers do not have a specific identifiable pathoanatomical origin for their pain. Additionally, disabilities associated with lower back pain have been a concern, and a predominant portion of the population was affected in the age group of 50-54. Owing to such numbers, the market is favored positively.

The growing incidence of mental illnesses has been of primary help for the market’s growth.

The global worries and attention for treating mental illnesses have been growing globally. Alongside, the disease burden within countries like India is growing. In 2017, around 197 million Indians, or around 14.3% of the total population had anxiety worries, and around 46 million had depression. The contribution of mental disorders to the total disease burden in India in terms of disability-adjusted life years has soared from 2.5% in 1990 to 4.7% in 2017. Within the body, phenylalanine gets converted into other forms of amino acids, known as tyrosine. Tyrosine in turn gets converted into L-dopa, norepinephrine, and epinephrine. Other forms of anti-depressants also follow the same method. Key researchers have highlighted that numbers would reach 3x in the coming decade for people afflicted with depression owing to peer pressure, high competition amongst masses, coupled with the growing urban population.

Inquiry Before Buying @ https://www.industryarc.com/reports/request-quote?id=513387

Global D-Phenylalanine Market Challenges

Health side-effects like intellectual disabilities have been a key market impeding factor.

Phenylalanine has shown side effects on a number of people. D-Phenylalanine can cause intellectual disabilities, brain damage, seizures, and other problems, especially with people suffering from PKU- disorder phenylketonuria. Furthermore, artificial sweetener aspartame has added many medications, diet foods, and diet sodas. Additionally, rheumatoid arthritis has been used with mixed results to treat chronic pain. Furthermore, people have rated it one of three stars for its effectiveness against osteoarthritis and rheumatoid arthritis. Symptomatic knee OA occurs in 10% of men while around 13% in women within the U.S.

Global D-Phenylalanine Industry Outlook

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the global Global D-Phenylalanine. Top-10 Global D-Phenylalanine key companies are-

  1. Kyowa
  2. Maidan Biology
  3. Tianjin Tianin
  4. Bafeng Pharmaceutical
  5. Jinghai Pharm
  6. Jiahe Biotech
  7. Xiyue Pharmaceutical
  8. Dongchem Bioengineering
  9. Abott
  10. Pfizer

Recent Developments

In January 2022, Jnana Therapeutics announced the appointment of John Throup as the Ph.D., Senior Vice President, and Head of Development. Additionally, the appointment is pivotal in treating and leading the research needed to treat cases of PKU. Phenylketonuria (PKU) is an inherited metabolic disorder caused by a deficiency of the enzyme phenylalanine hydroxylase (PAH). This enzyme is required for the breakdown of phenylalanine (Phe), an amino acid found in all protein-containing foods.

In January 2022, a recent clinical study took place, which evaluated and explored the mechanism by which SARS- COV-2 inhibits the synthesis of inflammatory marker IFN-?. The interaction was between cellular Grb 10- interacting GYF (glycine, tyrosine, phenylalanine) protein 2/4Eukaryotic homologous protein (GIGYF2/4EHP) complex was validated using the Proximity Ligation Assay (PLA).

In September 2021, Synlogic, Inc., a clinical-stage company, announced positive data from clinical studies evaluating both SYNB1618 and SYNB1934, investigational Synthetic Biotic™ medicines for the treatment of phenylketonuria (PKU). SYNB1618 demonstrated clinically meaningful reductions of phenylalanine (Phe) at several dose levels, across multiple time points and SYNB1934, an optimized strain evolved from SYNB1618, demonstrated two-fold higher activity than SYNB1618 in a head-to-head Phase 1 study in healthy volunteers, as measured by biomarkers of Phe metabolism.

Direct Purchase @ https://www.industryarc.com/purchasereport.php?id=513387

Key Takeaways

Geographically, North America’s d- phenylalanine market held a dominant market share in the year 2021. It is owing to the presence of both factors, for one, robust demand is catered by the regions such as the U.S. and Canada for various applicative uses such as helping depression or relieving various forms of pain. Secondly, the presence of robust medical infrastructure allows for optimal use of such ingredients.

Growing cases of depression, lower back pain, and various other forms of diseases have been a key market driver. However, ill-effects or side effects post-consumption of such medicines have hindered the overall market growth.

A detailed analysis of strengths, weaknesses, opportunities, and threats will be provided in the Global D-Phenylalanine Market Report.

Relevant Titles

A. Antidepressant Drugs Market

https://www.industryarc.com/Research/Antidepressant-Drugs-Market-Research-502395

B. Geriatric Medicines Market

https://www.industryarc.com/Report/17352/geriatric-medicines-market.html

For more Food and Beverage Market related reports, please click here

About IndustryARC: IndustryARC primarily focuses on Cutting Edge Technologies and Newer Applications market research. Our Custom Research Services are designed to provide insights on the constant flux in the global supply-demand gap of markets. Our strong team of analysts enables us to meet the client research needs at a rapid speed, with a variety of options for your business. Any other custom requirements can be discussed with our team, drop an e-mail to sales@industryarc.com to discuss more about our consulting services

Tags: Global D-Phenylalanine Market size, Global D-Phenylalanine industry outlook, Global D-Phenylalanine Market report, Global D-Phenylalanine top 10 companies, Global D-Phenylalanine Market share, Global D-Phenylalanine industry, Global D-Phenylalanine Market

See Campaign: https://www.industryarc.com/reports/request-quote?id=513387

Contact Information:

Venkat Reddy Sales Director Email: venkat@industryarc.com Website: https://www.industryarc.com Phone: (+1) 970-236-3677

Tags:
PR-Wirein, Reportedtimes, Extended Distribution, Research Newswire, English

Contact Information:

Venkat Reddy
Sales Director
Email: venkat@industryarc.com
Website: https://www.industryarc.com
Phone: (+1) 970-236-3677

Add Comment

Click here to post a comment

Your email address will not be published. Required fields are marked *